Bill Sponsor
House Simple Resolution 280
117th Congress(2021-2022)
Expressing the sense of the House of Representatives that decades of policies rooted in socialism have stifled United States domestic pharmaceutical drug manufacturing and left the United States exposed to the hostile actions and unfair trade practices of the People's Republic of China.
Introduced
Introduced
Introduced in House on Mar 26, 2021
Overview
Text
Introduced
Mar 26, 2021
Latest Action
Mar 29, 2021
Origin Chamber
House
Type
Simple Resolution
Simple Resolution
A form of legislative measure introduced and potentially acted upon by only one congressional chamber and used for the regulation of business only within the chamber of origin. Depending on the chamber of origin, they begin with a designation of either H.Res. or S.Res. Joint resolutions and concurrent resolutions are other types of resolutions.
Bill Number
280
Congress
117
Policy Area
Foreign Trade and International Finance
Foreign Trade and International Finance
Primary focus of measure is competitiveness, trade barriers and adjustment assistance; foreign loans and international monetary system; international banking; trade agreements and negotiations; customs enforcement, tariffs, and trade restrictions; foreign investment. Measures concerning border enforcement may fall under Immigration policy area.
Sponsorship by Party
House Votes (0)
No House votes have been held for this bill.
Summary

This resolution commits to the use of competitive free market and free trade policies to combat national security threats caused by China and its attacks on the U.S. pharmaceutical manufacturing base.

The resolution urges the United States to (1) remove tax, regulatory, and debt burdens and barriers that have weakened this base; (2) empower the U.S. Trade Representative to take specified actions to counter harmful and unfair trade practices by China; (3) address shortcomings in Food and Drug Administration data collection related to foreign-sourced pharmaceutical ingredients; and (4) identify and streamline regulatory hurdles that have impeded the U.S. pharmaceutical manufacturing base.

Text (1)
March 26, 2021
Actions (4)
03/29/2021
Referred to the Subcommittee on Health.
03/26/2021
Referred to the Committee on Ways and Means, and in addition to the Committees on Foreign Affairs, and Energy and Commerce, for a period to be subsequently determined by the Speaker, in each case for consideration of such provisions as fall within the jurisdiction of the committee concerned.
03/26/2021
Referred to the Subcommittee on Trade.
03/26/2021
Introduced in House
Public Record
Record Updated
Jan 11, 2023 1:47:55 PM